eBioscience Releases 32 New Clinical Flow Cytometry Reagents Optimized for Immunophenotyping of Hematologic Malignancies

08 Apr 2011
Share
eBioscience, a world leader in immunology and oncology flow cytometry reagents expands one of the world’s most trusted selections of antibodies, ELISAs and proteins for Life Science and diagnostic research to include 32 new products for the immunophenotyping of hematologic malignancies.

According to Robin Vedova, Director of Clinical Diagnostics at eBioscience, “The quality we put into our clinical flow cytometry reagents has been established by providing highly reliable research reagents to some of the most discerning scientists worldwide.” eBioscience reagents have been cited in over 16,000 publications during the last 10 years.

Considered one of the industry’s leading providers of reagents for multicolor flow cytometry, eBioscience continuously expands its comprehensive and innovative portfolio of antibodies, fluorochromes and reagents for immunology, oncology, cell biology, stem cell biology and diagnostics. Often first to market with critical reagents, eBioscience develops greater than 800 new products for multicolor flow cytometry annually.

The Clinical Flow Cytometry Reagent product line, introduced in 2009, adds to eBioscience’s reputation as a vendor of outstanding value. Their rapidly expanding portfolio of clinically relevant products is optimized for the clinical laboratory user. The antibodies are packaged in flexible sizes to help manage precise budgets. All sizes are formulated at 5µL/test to ensure efficient multicolor immunophenotyping by reducing the ratio of reagent solution to sample volume—critical for conserving precious samples.

The selection of fluorochrome formats is extensive, to address the wide variety of cytometers now found in clinical laboratories and provide the flexibility required for custom panel design. The GMP environment under which these clinical reagents are manufactured assures outstanding signal to noise and >90% purity. eBioscience reagents are manufactured for consistent performance and lot-to-lot consistency, thus preventing costly repeat testing. This commitment to quality and value ensures reliable data throughout long-term studies.

The rapidly expanding portfolio of clinical reagents will be showcased at the American Association for Cancer Research (AACR) 102nd Annual Meeting April 2 – 6 Orlando, Florida and also at the XXVI Congress of the International Society for Advancement of Cytometry (CYTO2011), May 21 – 25, 2011 Baltimore, Maryland.

Request Info


Company website

eBioscience